Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Neurology · C9ORF72-Related Huntington Disease-Like Syndrome

Understanding Your Diagnosis: C9ORF72 HD-Like Syndrome

At a Glance

A C9ORF72 repeat expansion can cause Huntington disease-like movement, mood, and cognitive symptoms after a negative HTT test. It is also linked to ALS and frontotemporal dementia, but variable expressivity means people do not necessarily develop every condition.

For many people with Huntington’s-like symptoms, the journey to a diagnosis is a long and exhausting process often called a diagnostic odyssey [1]. You may have spent years visiting different specialists, undergoing repeated testing, and perhaps even feeling that your symptoms were being dismissed because the standard tests were coming back negative [2].

If you were tested for Huntington’s disease and the result for the HTT gene was negative, but your symptoms—such as involuntary movements, mood changes, or cognitive shifts—continued to progress, doctors may describe your condition as an HD phenocopy [3]. An HD phenocopy is a clinical description, not a final diagnosis; it means a condition that looks and acts like a specific disease (in this case, Huntington’s) but is caused by a different genetic or environmental factor [4].

Receiving a diagnosis of a C9ORF72 expansion can be both validating and overwhelming. It provides an answer to the “why” behind your symptoms, but it also places you within a complex biological spectrum that links three seemingly different diseases [5].

The Rarity of the C9ORF72 HD-Like Variant

The C9ORF72 expansion is a rare cause of Huntington’s-like symptoms. While Huntington’s disease itself is well-known, this specific variant is found in only about 1% to 2% of people in specific research cohorts who have HD-like symptoms but test negative for the HTT mutation [6][7]. This estimate varies depending on the referral population, ancestry, and testing methods.

Because it is so rare, many healthcare providers may not have encountered it before. This rarity can add to the feeling of isolation for families, as the resources and support groups built for classic Huntington’s may not always feel like a perfect fit for your specific biological reality [8].

One Gene, Three Diseases

The most unique—and sometimes frightening—aspect of the C9ORF72 expansion is its biological link to two other major neurological conditions: Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) [5].

Biologically, the expansion in this gene creates abnormal RNA and proteins in the brain and spinal cord [9][10]. Depending on which part of the nervous system is most affected, the same genetic expansion can show up in different ways:

  • Movement focus: If the expansion primarily affects the basal ganglia (the brain’s movement control center), it looks like Huntington’s disease, causing chorea (involuntary, jerky movements) or parkinsonism [11][12].
  • Cognitive and Behavioral focus: If it affects the frontal and temporal lobes of the brain, it can lead to Frontotemporal Dementia (FTD), involving significant personality changes, loss of empathy, or language difficulties [13].
  • Motor Neuron focus: If it affects the motor neurons that control muscles, it leads to ALS (Lou Gehrig’s disease), causing muscle weakness, wasting, and twitching [14].

Understanding Your Specific Path

It is important to understand that having this expansion does not mean you will definitely develop every symptom of ALS or FTD. This is due to variable expressivity, which means the same genetic change can act differently in different people [15].

However, your care team may monitor you for “clues” that aren’t typical for classic Huntington’s. These might include:

  • Early psychiatric symptoms: Some case reports suggest patients may experience significant behavioral changes or psychosis, though it is not certain these are more common than in classic HD [11].
  • Motor neuron signs: Doctors may check for muscle wasting (atrophy) or small muscle twitches (fasciculations) that are characteristic of the ALS side of the spectrum [14].
  • Seizures: While rare in classic HD, seizures are occasionally reported in the wider C9ORF72 spectrum, though they are neither required nor diagnostic [11].

Navigating the Emotional Impact

The transition from thinking you had Huntington’s to learning you have a C9ORF72 expansion can be a significant emotional pivot. Some people feel a sense of relief at finally having an answer, while others feel grief, anxiety, or confusion when this new result arrives [16].

This diagnosis also changes the conversation for your family. Unlike classic Huntington’s, where children are at risk for the same disease, a family member of someone with a C9ORF72 expansion might be at risk for a different condition in the spectrum, such as ALS or FTD [15]. Working with a genetic counselor who is familiar with the C9ORF72 spectrum is essential for helping your relatives understand their own risks and testing options [17].

Though your biological “address” has changed, the need for compassionate, multidisciplinary care—including physical therapy, speech therapy, and psychological support—remains the same [18].

Common questions in this guide

What does a C9ORF72 expansion mean after a negative Huntington disease test?
It means a repeat expansion in the C9ORF72 gene was found, providing a genetic explanation for symptoms that resemble Huntington disease even though the HTT test was negative. This situation is often called an HD phenocopy, meaning a Huntington-like condition caused by something else.
Does having a C9ORF72 expansion mean I will develop ALS or frontotemporal dementia?
No. The expansion can affect movement, thinking, behavior, or motor neurons in different ways, and variable expressivity means people with the same expansion can have different symptoms. Your care team may monitor for signs associated with ALS or frontotemporal dementia, but the result does not mean you will definitely develop either condition.
What symptoms may doctors monitor with C9ORF72-related disease?
Monitoring may include involuntary movements or parkinsonism, changes in behavior, personality, thinking, or language, and signs of motor-neuron involvement such as weakness, muscle wasting, or twitching. Seizures can occur but are uncommon and are not required for diagnosis. The monitoring plan should be tailored to your symptoms.
Could my relatives be at risk if I have a C9ORF72 expansion?
Some relatives may be at risk of carrying the expansion, but variable expressivity means a family member could experience different symptoms, including movement, ALS-related, or frontotemporal symptoms. A genetic counselor familiar with C9ORF72 can review the family history, explain testing options, and discuss what the results could mean.
What care may be helpful after a C9ORF72 diagnosis?
Care is usually individualized and multidisciplinary. Depending on your symptoms, it may include neurologic follow-up, physical therapy, speech therapy, psychological support, and monitoring such as speech or respiratory evaluations.
Why can it take so long to diagnose C9ORF72 HD-like syndrome?
The symptoms can resemble Huntington disease, but a standard HTT test may be negative, leading to additional evaluations during a long diagnostic process. Because C9ORF72 HD-like syndrome is rare, it may not be familiar to every healthcare provider.

Get notified when new evidence is published on Huntington disease-like syndrome due to C9ORF72 expansions.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    Whole-exome sequencing in adult patients with developmental and epileptic encephalopathy: It is never too late.

    Minardi R, Licchetta L, Baroni MC, et al.

    Clinical genetics 2020; (98(5)):477-485 doi:10.1111/cge.13823.

    PMID: 32725632
  2. 2

    Diagnostic odyssey of Guillain-Barré syndrome in children.

    Kobayashi Takahashi Y, Hayakawa I, Abe Y

    Brain & development 2024; (46(2)):108-113 doi:10.1016/j.braindev.2023.10.004.

    PMID: 37914621
  3. 3

    Non-Huntington's disease chorea: an expanding universe with acquired causes.

    Cardoso F, Maia D, Maciel R, et al.

    Brain : a journal of neurology 2026; (149(6)):1860-1873 doi:10.1093/brain/awag038.

    PMID: 41612618
  4. 4

    Expanding the Spectrum of Genes Involved in Huntington Disease Using a Combined Clinical and Genetic Approach.

    Mariani LL, Tesson C, Charles P, et al.

    JAMA neurology 2016; (73(9)):1105-14 doi:10.1001/jamaneurol.2016.2215.

    PMID: 27400454
  5. 5

    Expanding the spectrum of C9ORF72-related neurodegenerative disorders in the Greek population.

    Kartanou C, Kontogeorgiou Z, Rentzos M, et al.

    Journal of the neurological sciences 2022; (442()):120450 doi:10.1016/j.jns.2022.120450.

    PMID: 36252286
  6. 6

    Screening for the C9ORF72 expansion in Greek Huntington Disease phenocopies and controls and meta-analysis of current data.

    Rikos D, Marogianni C, Provatas A, et al.

    Tremor and other hyperkinetic movements (New York, N.Y.) 2020; (10()):5 doi:10.5334/tohm.61.

    PMID: 32775019
  7. 7

    C9orf72 Hexanucleotide Repeat in Huntington-Like Patients: Systematic Review and Meta-Analysis.

    Alva-Diaz C, Alarcon-Ruiz CA, Pacheco-Barrios K, et al.

    Frontiers in genetics 2020; (11()):551780 doi:10.3389/fgene.2020.551780.

    PMID: 33240313
  8. 8

    Ultra-rare ultra-care: Assessing the impact of caring for children with ultra rare diseases.

    Domaradzki J, Walkowiak D

    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2024; (48()):78-84 doi:10.1016/j.ejpn.2023.12.003.

    PMID: 38071849
  9. 9

    Insights into the pathogenic mechanisms of Chromosome 9 open reading frame 72 (C9orf72) repeat expansions.

    Todd TW, Petrucelli L

    Journal of neurochemistry 2016; (138 Suppl 1()):145-62 doi:10.1111/jnc.13623.

    PMID: 27016280
  10. 10

    Blocking RAN translation without altering repeat RNAs rescues C9ORF72-related ALS and FTD phenotypes.

    Jiang X, Schaeffer L, Patni D, et al.

    Science (New York, N.Y.) 2026; (391(6785)):eadv2600 doi:10.1126/science.adv2600.

    PMID: 41643021
  11. 11

    C9orf72 and its Relevance in Parkinsonism and Movement Disorders: A Comprehensive Review of the Literature.

    Bourinaris T, Houlden H

    Movement disorders clinical practice 2018; (5(6)):575-585 doi:10.1002/mdc3.12677.

    PMID: 30637277
  12. 12

    Hereditary chorea - what else to consider when the Huntington's disease genetics test is negative?

    Malek N, Newman EJ

    Acta neurologica Scandinavica 2017; (135(1)):25-33 doi:10.1111/ane.12609.

    PMID: 27150574
  13. 13

    Revisiting the neuropsychiatry of Huntington's disease.

    Teixeira AL, de Souza LC, Rocha NP, et al.

    Dementia & neuropsychologia 2016; (10(4)):261-266 doi:10.1590/s1980-5764-2016dn1004002.

    PMID: 29213467
  14. 14

    Concurrent Amyotrophic Lateral Sclerosis and Huntington's Disease.

    Takahashi R, Furuta M, Nagashima K, Ikeda Y

    Internal medicine (Tokyo, Japan) 2025; (64(2)):297-300 doi:10.2169/internalmedicine.3232-23.

    PMID: 38897956
  15. 15

    Who and Why? Requests for Presymptomatic Genetic Testing for Amyotrophic Lateral Sclerosis/Frontotemporal Dementia vs Huntington Disease.

    Amador MDM, Gargiulo M, Boucher C, et al.

    Neurology. Genetics 2021; (7(1)):e538 doi:10.1212/NXG.0000000000000538.

    PMID: 33376800
  16. 16

    Lessons learned from 30 years of presymptomatic testing in Huntington Disease.

    Pierron L, Hébert M, Gargiulo M, Durr A

    Revue neurologique 2025; (181(9)):852-862 doi:10.1016/j.neurol.2025.07.009.

    PMID: 41238315
  17. 17

    Current knowledge of Huntington's disease-like 2 genetic testing, clinical presentation, and patient experiences: A systematic review.

    Hoffmann K, White S, Sexton A

    Journal of Huntington's disease 2026; (15(3)):293-316 doi:10.1177/18796397251411109.

    PMID: 41564273
  18. 18

    Predictive testing for neurodegenerative diseases in the age of next-generation sequencing.

    Goldman J, Xie S, Green D, et al.

    Journal of genetic counseling 2020; doi:10.1002/jgc4.1342.

    PMID: 33090625

This page is for informational purposes only and is not medical advice; it cannot diagnose you or predict whether ALS or FTD will develop. Discuss your C9ORF72 results and family-testing options with your neurologist and genetic counselor.